Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nexalin Technology, Inc. ( (NXL) ) just unveiled an update.
On May 4, 2025, Nexalin Technology, Inc. entered into an underwriting agreement with Maxim Group LLC for a public offering of 3,850,000 shares of its common stock at $1.30 per share, expected to close on May 6, 2025. The gross proceeds are anticipated to be approximately $5.0 million, which Nexalin plans to use for working capital, sales and marketing, product development, and capital expenditures, potentially impacting its operational capabilities and market presence.
More about Nexalin Technology, Inc.
Nexalin Technology, Inc. designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic. The company’s products are non-invasive, utilizing bioelectronic medical technology to treat mental health issues by penetrating deep brain structures associated with these disorders. Their Gen-2 15 milliamp neurostimulation device is approved in China, Brazil, and Oman.
Average Trading Volume: 156,298
Technical Sentiment Signal: Hold
Current Market Cap: $23.86M
See more data about NXL stock on TipRanks’ Stock Analysis page.